Basics of HIV Drug Resistance Mutations

Basics of HIV Drug Resistance Mutations

Presenters

Francesca Ceccherini Silberstein, PhD
University of Rome Tor Vergata
Douglas D. Richman, MD
University of California San Diego
Robert W. Shafer, MD
Stanford University

Start

December 14, 2022 - 10:00 AM

End

December 14, 2022 - 11:30 AM

Add to iCal Calendar

This is the rescheduled date for our postponed October 27, 2022, webinar. If you have previously registered for the prior date, your registration has automatically been converted.

Overview

Assessment of Needs

This webinar will highlight the recent IAS–USA 2022 Update of the Drug Resistance Mutations in HIV-1, published on September 23, 2022. This webinar will reivew the basic principles of HIV drug resistance mutations. It will provide an overview of the article, particularly how to read and understand how it can be applied in clinical practice. Additionally, it will discuss the recent update and new drugs, including lenacapavir and doravirine, and how to manage drug resistance in patients with the availability of the various new drugs. 

Learning Objectives

Upon completion of this activity, learners will be able to:

  • Describe basic principles of HIV drug resistance mutations
  • Explain how to understand and interpret the information presented on the IAS–USA 2022 Update of the Drug Resistance Mutations in HIV-1
  • Identify recent updates to the IAS–USA 2022 Update of the Drug Resistance Mutations in HIV-1 and how they apply to the management of drug resistance in patients

Registration

Who Should Attend

This webinar is designed for clinical decision makers who are actively involved in HIV care and research, including physicians, physician assistants, nursing professionals, pharmacists, and other health care professionals.

Individual registration is required in order to receive CME credit or a certificate of participation.

Registration closes on December 14, 2022, 10:30 AM (PT).

Certificates will be available after the completion of the evaluation and claim form.

For more information or questions, please contact the registration department at registration@iasusa.org or 415-544-9400.

Conflicts of Interest

In the interest of maintaining the independence of its continuing education activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships with ineligible companies (previously defined as “commercial interests”) that they or their spouses or partners have had within the past 24 months. Any real or apparent conflicts of interest of those parties are resolved prior to the continuing education activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA continuing education activity.

The ACCME defines ineligible companies as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

The IAS–USA will identify and resolve ahead of time any possible conflicts of interest that may influence CME activities with regard to exposition or conclusion. Information about financial relationships with ineligible companies information for the presenter and planners/reviewers are below and in the presentation. All relevant financial relationships with ineligible companies have been mitigated.

Presenters

Dr Ceccherini-Sil-berstein has been a consultant to ViiV Healthcare, Gilead Sciences, Inc, and Merck Sharp & Dohme, Inc, and has received research grants from ViiV Healthcare, Gilead Sci-ences, Inc, and Merck Sharp & Dohme, Inc. (Updated 11/02/22)

Dr Richman has been a consultant to Antiva Biosciences and Merck & Co, Inc, and serves as Chair of the Data Management Committee of Gilead Sciences, Inc. (Updated 10/01/22)

Dr Shafer has received research grants from Janssen Therapeutics, Vela Diagnostics, and InSilixa, Inc, and personal consulting fees from Abbott Diagnostics. (Updated 11/02/22)

Planner/Reviewer

Planner/Reviewer 1 has no relevant financial relationships with ineligible companies to disclose. (Updated 10/01/22)

Planner/Reviewer 1 has no relevant financial relationships with ineligible companies to disclose. (Updated 10/01/22)

CME Credits

The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The IAS–USA designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC Point

ABIM MOCSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Nursing Credits

These activities are eligible for ANCC credit, see final CNE activity announcement for specific details.

Pharmacy Credits

Accreditation Council for Pharmacy Education logo These activities are eligible for ACPE credit, see final CPE activity announcement for specific details.

Grant Support

This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from ineligible companies. Per IAS–USA policy, any effort that uses grants from ineligible companies must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.

PLATINUM SUPPORTERS

Gilead Sciences, Inc.
Merck & Co, Inc.
ViiV Healthcare

SILVER SUPPORTER

Janssen Therapeutics

BRONZE SUPPORTER

Theratechnologies, Inc.

 

Frequently Asked Questions

View our list of FAQs about attending a webinar.

Further Questions?
Please contact the registration department at registration@iasusa.org or 415-544-9400.